Drug intelligence / Profile preview

PN-SIA49

Development stage: Preclinical
Lead developer: Pomone
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intranasal, Intraperitoneal, Inhalation

Overview

PN-SIA49 is a cross-reactive human monoclonal antibody developed by Pomona Ricerca for the treatment and prevention of influenza infections caused by group 1 strains. The antibody targets conserved regions of the group 1 hemagglutinin (HA) protein, a surface glycoprotein essential for viral attachment and entry into host cells. By binding to these conserved epitopes, PN-SIA49 provides broad neutralization against multiple group 1 influenza A viruses, including H1N1 and H5N1. The candidate is currently in preclinical development.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on PN-SIA49.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PN-SIA49.

Explore the full profile